Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in older patients with Hodgkin lymphoma
NCT05627115Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Mar 2024
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by University College London. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05627115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627115.